about
Use of magnetic resonance imaging in pharmacogenomicsNeural correlates of erotic stimulation under different levels of female sexual hormonesNeural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropionNeural activation in humans during a simple motor task differs between BDNF polymorphisms.The neural substrate of positive bias in spontaneous emotional processingProtocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly populatGenetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapiesClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake InhibitorsIndividualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial.Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs.Gene expression and proliferation biomarkers for antidepressant treatment resistance.CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study.Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx).The iconography of mourning and its neural correlates: A functional neuroimaging studyPregnancy exposure to citalopram - Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood.Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers.Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker.Predicting CYP2D6 phenotype from resting brain perfusion images by gradient boosting.Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.High rate of hypoglycemia in 6770 type 2 diabetes patients with comorbid dementia: A multicenter cohort study on 215,932 patients from the German/Austrian diabetes registry.High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors.Multimodal MEMPRAGE, FLAIR, and [Formula: see text] Segmentation to Resolve Dura and Vessels from Cortical Gray MatterImpact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.Prevalence and comorbidity of chronic pain in the German general population.Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.Routine micromethod for the determination of vitamin K1 in human plasma.Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.A Computerized Version of the Scrambled Sentences Test.Gene regulatory biomarker identification for skin toxicities induced by EGFR inhibitor treatment.Effect of paroxetine and bupropion on human resting brain perfusion: an arterial spin labeling study.Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans.Population nutrikinetics of green tea extract.
P50
Q27011768-3FBA9F79-049B-40D4-A465-C15DB950CBA1Q27319656-4EE4E4A6-3921-4DB9-9A04-D1554514117FQ30503382-BC7A9591-09CD-42A9-AFFC-623D47A478FEQ33610183-82A52CC9-8B27-42AC-B863-692ECBDEB417Q33747683-AAA71DF6-2B81-448B-92BF-05010EAFB878Q33996086-D577F487-3015-4F0E-86C5-CAFBECCCA58EQ34273354-8674EE85-C949-42AD-B82A-FA01AB5C37D2Q35558084-0944A798-9B0E-444D-B48D-8007BCB097E1Q35715254-44D30022-EE8F-44E5-8D4D-7F8AE70CFE19Q35782820-AF5B365D-3DED-4594-A530-8BCFA16EA7E7Q35883249-11E2D991-DA89-4FDA-BEFD-77F6162D7E14Q35998552-E1A103BE-3680-4B8D-91A8-CFBB0D91CFE9Q38042441-05D421E4-74A8-4783-A8C1-65E5AAD5566AQ38146384-6462B275-BB6E-4018-953C-E91D97FF3D5EQ38258243-5FABC17F-270A-48CC-B10F-69EADAF3E7CAQ38432665-1A55C2F7-2DF1-465B-9227-A72CF6CC6C04Q38444087-AB3DA74B-BBDA-4322-BB41-465162A3F2AEQ38509732-934AECAC-BA65-48E0-A1B0-86B1D4EAEBA0Q38663993-3D27F570-5E0C-43BA-BBD2-A1BCAD9093ECQ38690168-33890837-A894-41C1-863C-16CD57917F5CQ38701702-6515C952-C919-4F3A-9ABE-6B4EA87C2C71Q39062032-E50052FA-EA54-4921-AC18-413CC7E0269FQ39293823-D4184B18-742A-45A3-B97B-F19EC690DDB9Q39589817-2E0C6D68-2765-4CDD-A6DA-555C9489F117Q40440977-CF1BFCDE-DB98-42B3-8CAC-5700557841BBQ40945311-B0FB8C3C-2981-4E46-AEB2-11A80DB41519Q41127481-0F4623F9-F59F-4E39-BB0D-544F834E21DAQ41289945-F8005D65-6487-4C7E-A18C-C132D9624536Q41786264-215905E4-24FB-403B-92BE-8EA48D7501C0Q42904774-42664F89-701D-4A24-B8AB-E2FE4786F903Q44527108-7026B270-975C-4FAA-B12D-6DF3785EA644Q44775271-8B6BF59D-9830-4C9F-B4D1-8C68D986DFD0Q46091944-FADBA875-C874-4641-85AD-161208AF01C5Q46250648-5B2A23A7-67DF-4A48-8AA3-CFE043AAE909Q47621835-060CB933-7AF7-4870-A3F1-7286EBC77B1EQ47644375-AE713540-C6D0-4B52-9A10-FBA378DC3D25Q47922516-E2944E18-F8D2-495B-B157-CBAD448A92E5Q48598749-9FF76D88-BCF7-4873-B114-B768FAF181FEQ48952710-F47365D8-883B-4986-8DEA-6091E9652F3FQ50146225-27AAD8F1-DE6F-4525-8494-D06982334636
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Julia C Stingl
@ast
Julia C Stingl
@en
Julia C Stingl
@es
Julia C Stingl
@nl
Julia C Stingl
@sl
type
label
Julia C Stingl
@ast
Julia C Stingl
@en
Julia C Stingl
@es
Julia C Stingl
@nl
Julia C Stingl
@sl
altLabel
Julia Stingl
@en
prefLabel
Julia C Stingl
@ast
Julia C Stingl
@en
Julia C Stingl
@es
Julia C Stingl
@nl
Julia C Stingl
@sl
P214
P1053
H-2410-2013
P106
P1153
36621918100
P21
P214
P2456
P31
P3829
P496
0000-0002-1566-8156
P735
P7859
viaf-35245755